Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

GermanyBack to Germany

Clinical trials in Weiden in der Oberpfalz

11 clinical trials in Weiden in der Oberpfalz, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Weiden in der Oberpfalz at a glance
11
clinical trials
  • Paediatric trials0
  • Research sites0
Type of trial
Recruitment status
Quick filters

11 trials in Weiden in der Oberpfalz

Open in trial search

Arteriosclerosis

Recruiting
InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Pelacarsen
  • Sponsor:Novartis Pharma AG

Chronic lymphocytic leukaemia+1

Recruiting
Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Obinutuzumab
  • Sponsor:University Of Cologne

Arteriosclerosis

Not yet recruiting
Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Sponsor:Amgen Inc.

Arteriosclerosis

Not recruiting
Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Pelacarsen
  • Sponsor:Novartis Pharma AG

Bladder cancer

Not recruiting
Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Gastrooesophageal cancer

Not recruiting
Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Rectal cancer

Not recruiting
Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Goethe University Frankfurt

Rectal cancer

Not recruiting
Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Heidelberg University

Ductal adenocarcinoma of pancreas

Not recruiting
Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Gemcitabine
  • Sponsor:Panbela Therapeutics Inc.

Colon cancer stage II+1

Not recruiting
Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Technische Universitaet Dresden

Prostate cancer

Not recruiting
Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Apalutamide
  • Sponsor:Janssen - Cilag International

Other cities in Germany

The busiest research cities in the country

All 515 cities in Germany

Clinical research in Weiden in der Oberpfalz

What the registry says about research in the country

01 Weiden in der Oberpfalz
Cardiovascular Diseases
Clinical research in Weiden in der Oberpfalz includes studies focused on cardiovascular disease and atherosclerotic cardiovascular disease (ASCVD). These trials are designed to test whether new lipoprotein(a)-lowering approaches can reduce major heart and stroke-related events. Reducing the risk of heart attack, stroke, and urgent coronary procedures Evaluating long-term safety and tolerability of new cardiovascular therapies Preventing first major cardiovascular events in people with elevated Lp(a) The overall goal is to improve prevention for people at high risk of serious cardiovascular complications.
Neoplasms
A strong oncology portfolio is being studied, covering several cancers such as bladder cancer, prostate cancer, and colorectal cancer. Research also extends to pancreatic, gastric, and oesophagogastric junction cancers, reflecting a broad effort to improve treatment outcomes. Testing new treatment combinations for high-risk non-muscle invasive bladder cancer Improving outcomes in high-risk prostate cancer and locally advanced disease Studying better strategies for colon and rectal cancer management, including organ preservation Assessing therapies for metastatic pancreatic ductal adenocarcinoma and upper gastrointestinal cancers These trials aim to refine cancer control, support organ-preserving care where possible, and evaluate whether adding new therapies can strengthen standard treatment.
Hematologic Malignancies
Research also includes blood cancers, especially chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). The studies are examining whether newer treatment approaches can better control disease and help tailor therapy duration to patient response. Comparing newer combination regimens for untreated CLL/SLL Using measurable disease response to guide treatment planning Evaluating effectiveness and disease control over time This area focuses on improving precision in treatment selection while maintaining strong long-term outcomes.
Bladder Cancer
One line of oncology research is centered on high-risk non-muscle invasive bladder cancer. The trials are exploring whether adding a new immune-based therapy can improve disease control compared with standard bladder cancer treatment alone. Testing a new approach for patients with high-risk bladder cancer Assessing whether treatment combinations improve response and event-free survival Supporting better control of early-stage but high-risk disease The emphasis is on strengthening treatment effectiveness while maintaining bladder preservation when possible.
Prostate Cancer
Trials in high-risk localized and locally advanced prostate cancer are studying whether adding a new therapy to standard radiation-based care can improve outcomes. This work is aimed at reducing the chance of disease spread and making treatment more effective. Improving control of high-risk prostate cancer Evaluating treatment added to primary radiation therapy Focusing on prevention of metastatic progression These studies reflect a broader effort to optimize therapy for patients with aggressive disease features.
Colorectal Cancer
In colorectal cancer, research covers colon cancer stage II, rectal cancer stage II, and more advanced rectal cancer settings. The trials are examining how treatment can be better matched to risk, with a strong interest in preserving the rectum and avoiding unnecessary surgery. Guiding adjuvant treatment decisions in stage II colon cancer Studying organ-preserving strategies in rectal cancer Improving disease-free survival and local disease control The research aims to personalize care while protecting quality of life and long-term cancer control.
Rectal Cancer
A dedicated set of studies addresses intermediate-risk, high-risk, and locally advanced rectal cancer. These trials are exploring treatment sequences that may improve organ preservation and reduce the need for major surgery. Testing approaches that support rectum preservation Comparing combined treatment strategies for locally advanced disease Measuring disease-free survival and long-term control This research is focused on balancing cancer eradication with the goal of maintaining normal bowel function and avoiding a permanent stoma.
Gastroesophageal Cancer
Trials in locally advanced resectable adenocarcinoma of the oesophagogastric junction and stomach cancer are evaluating whether adding a newer treatment to perioperative standard care can improve outcomes. The main aim is to strengthen event-free survival before and after surgery. Testing combination therapy in gastric and oesophagogastric junction cancer Assessing whether treatment intensification improves survival-related outcomes Supporting better disease control around surgery These studies are intended to improve the effectiveness of standard treatment for potentially curable upper gastrointestinal cancers.
Pancreatic Cancer
Research in metastatic pancreatic ductal adenocarcinoma is looking at whether a new therapy added to established chemotherapy can improve overall survival. This reflects the need for better options in an especially difficult-to-treat cancer. Evaluating survival benefit in metastatic disease Studying new treatment added to standard chemotherapy Seeking better control of advanced pancreatic cancer The studies aim to extend survival and improve treatment effectiveness in a high-need setting.
Research Activity in the City
Weiden in der Oberpfalz is hosting a focused but active clinical trial landscape with all identified studies currently recruiting. The work is concentrated in two main fields, cardiovascular medicine and oncology, across multiple research sites and investigators. Active recruitment across all identified studies Concentration in heart disease and cancer research Multiple sites supporting patient access to trials The local portfolio suggests a strong interest in both prevention-focused medicine and innovative cancer care.
Back to GermanyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.